Loading
A phase 3 trial of Linvoseltamab, Daratumumab in multiple myeloma, run by Regeneron Pharmaceuticals, now recruiting.
A Study to Compare Linvoseltamab and Daratumumab Treatment in High-Risk Smoldering Multiple Myeloma (HR-SMM) is a phase 3 interventional study registered as NCT07393282 by Regeneron Pharmaceuticals, with 270 participants planned, started 2026-05-21 and due to reach its primary completion in 2033-07-27. Interventions recorded: Linvoseltamab, Daratumumab. Conditions listed: High Risk Smoldering Multiple Myeloma (HR-SMM). No results are recorded here; the registry entry is the source.
Shares Linvoseltamab, Smouldering multiple myeloma, Regeneron, T-cell engagers (bispecific).
Shares Linvoseltamab, Smouldering multiple myeloma, Regeneron, T-cell engagers (bispecific).
Shares Linvoseltamab, Regeneron, T-cell engagers (bispecific), Multiple myeloma.
Shares Linvoseltamab, Regeneron, T-cell engagers (bispecific), Multiple myeloma.
Shares Linvoseltamab, Regeneron, T-cell engagers (bispecific), Multiple myeloma.
Shares Linvoseltamab, Regeneron, T-cell engagers (bispecific), Multiple myeloma.
Shares Linvoseltamab, Regeneron, T-cell engagers (bispecific), Monoclonal antibodies.
Shares Smouldering multiple myeloma, Daratumumab, Monoclonal antibodies, Multiple myeloma.